Last reviewed · How we verify

LifeBridge Health — Portfolio Competitive Intelligence Brief

LifeBridge Health pipeline: 3 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Bivalirudin with and without eptifibatide Bivalirudin with and without eptifibatide marketed Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide) Thrombin (Factor IIa) and Glycoprotein IIb/IIIa receptor Cardiovascular
Arixtra Arixtra marketed Antithrombin-III, Coagulation factor X Cardiovascular
Fascia Iliaca Nerve Block Fascia Iliaca Nerve Block marketed Pain Management / Regional Anesthesia

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for LifeBridge Health:

Cite this brief

Drug Landscape (2026). LifeBridge Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lifebridge-health. Accessed 2026-05-17.

Related